Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CS DiagnosticsCSDX EV-to-EBIT is 446.56 as of Aug. 01, 2026. The stock has 1 warning sign investors should review. Among 467 Medical Devices & Instruments companies, CS Diagnostics ranks worse than 99.14% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
CS Diagnostics's Enterprise Value for the quarter that ended in Dec. 2025 was $76.39 Mil.
CS Diagnostics's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.04 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CS Diagnostics EV-to-EBIT Related Terms
CS Diagnostics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for CS Diagnostics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, CS Diagnostics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CS Diagnostics EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CS Diagnostics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where CS Diagnostics's EV-to-EBIT falls into.
CS Diagnostics's current Enterprise Value is $17.42 Mil.
CS Diagnostics's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.04 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CS Diagnostics (CSDX) has a EV-to-EBIT of 446.56 as of Aug. 01, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on CS Diagnostics and its competitors. According to the industry distribution chart, CS Diagnostics ranks #463 out of 467 companies in the Medical Devices & Instruments industry, placing it in the top 99.1%.
Is CS Diagnostics' EV-to-EBIT too high?
CS Diagnostics' current EV-to-EBIT is 446.56. The Medical Devices & Instruments industry median EV-to-EBIT is 18.66. CS Diagnostics' value of 446.56 is 2293.1% above this industry median. Based on the distribution chart, CS Diagnostics ranks #463 out of 467 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does CS Diagnostics' EV-to-EBIT compare to NMTC and IRIX?
According to the Medical Devices & Instruments industry distribution chart, CS Diagnostics ranks #463 out of 467 companies for EV-to-EBIT. This places CS Diagnostics in the lower half of its industry. The industry median EV-to-EBIT is 18.66. CS Diagnostics' value of 446.56 is 2293.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.66, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CS Diagnostics's current EV-to-EBIT of 446.56 is 2293.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on CS Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CS Diagnostics's current EV-to-EBIT is 446.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CS Diagnostics stock overvalued right now?
CS Diagnostics (CSDX) has a current EV-to-EBIT of 446.56. The current EV-to-EBIT is 446.56 and 2293.1% above the Medical Devices & Instruments industry median of 18.66. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For CS Diagnostics (CSDX), the current EV-to-EBIT is 446.56 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CS Diagnostics Corp is a United States based Corporation, its focus is on improving therapy results and reducing side effects. In addition, it offers international companies in the medical industry access to markets and the service of approval of medical products in Europe and the MENA regions. Furthermore, it develops its own products with the aim of maximizing patient benefit.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSDX has been successfully added to your 
